Narrative review discusses tezepelumab for severe asthma in type 2-low patients on GINA Step 4–5 therapy

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published April 24, 2026 Medically reviewed May 24, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note tezepelumab for severe asthma in type 2-low patients, but await long-term data.

This narrative review addresses the role of tezepelumab in the management of severe asthma, with a specific focus on the type 2-low patient population. The scope of the discussion includes patients who are already prescribed GINA Step 4–5 ICS/LABA therapy, highlighting the context of current treatment guidelines.

The authors synthesize secondary outcomes related to therapeutic efficacy and biomarker correlations. Furthermore, the review explores real-world implementation considerations and identifies pharmacoeconomic and access barriers that may impact patient care. These points are discussed within the broader context of existing literature rather than primary trial data.

The authors explicitly note several limitations, including the inherent constraints of clinical trial evidence and potential population selection biases. Real-world applicability concerns are raised, alongside a clear need for long-term outcome data to better understand the drug's performance outside controlled settings. Funding or conflict of interest information was not reported.

Consequently, the practice relevance is tempered by these uncertainties. Clinicians should interpret the findings with caution, recognizing that the evidence base for tezepelumab in type 2-low patients remains evolving and requires further validation through long-term studies.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedApr 2026

View Original Abstract ↓

Approximately 40%–50% of patients prescribed GINA Step 4–5 ICS/LABA therapy remain inadequately controlled, and existing biologics are restricted by phenotypic eligibility criteria that exclude the substantial type 2-low patient population. Thymic stromal lymphopoietin (TSLP) is an epithelial-derived alarmin cytokine that functions as a key upstream orchestrator of both type 2 and non-type 2 inflammatory pathways in asthma pathogenesis. Tezepelumab, a human monoclonal antibody targeting TSLP, represents the first biologic approved for severe asthma without phenotype- or biomarker-restricted eligibility, including type 2-low disease, with the caveat that the magnitude of benefit is somewhat smaller in T2-low patients. This review provides a comprehensive analysis of tezepelumab’s molecular pharmacology, structural basis of target engagement, clinical pharmacokinetic/pharmacodynamic profile, pivotal clinical trial evidence, safety data, and regulatory positioning. We systematically evaluate tezepelumab’s mechanistic rationale, therapeutic efficacy, biomarker correlations, and real-world implementation considerations, including pharmacoeconomic and access barriers. Furthermore, we critically discuss the current limitations of clinical trial evidence, population selection biases, real-world applicability concerns, and the need for long-term outcome data. Future research directions encompassing predictive biomarker development, expansion into non-asthma indications, real-world evidence generation, and advanced mechanistic studies are outlined. Tezepelumab exemplifies precision respiratory medicine by targeting upstream inflammatory cascades and establishes a paradigm for next-generation asthma therapeutics.